Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.54 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.54 |
| ▸ | CACNB1 | Q02641 | 3/20 | 0.54 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.47 |
| ▸ | TACR2 | P21452 | 1/20 | 0.43 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2792739 | 0.91 | KCNH2 (0.57) | CACNA1BCACNA1CKCNH2CACNA1FDRD1 | |
| SCHEMBL2796749 | 0.86 | CACNA2D1 (0.73) | CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL2793051 | 0.84 | ALDH1A1 (0.46) | KCNH2 | |
| SCHEMBL2795615 | 0.83 | CACNA2D1 (0.54) | CACNA2D1CACNA1BCACNB1CACNA1CSLC6A3 | |
| SCHEMBL2791261 | 0.78 | HTT (0.54) | CACNA2D1CACNA1BCACNB1CACNA1CSLC6A3 | |
| SCHEMBL2790390 | 0.76 | CACNA2D1 (0.55) | CACNA2D1CACNA1BCACNB1CACNA1CTACR2 | |
| SCHEMBL2796408 | 0.76 | KCNH2 (0.54) | CACNA1BCACNA1CKCNH2CACNA1FDRD1 | |
| SCHEMBL2793260 | 0.74 | CACNA2D1 (0.53) | CACNA2D1CACNA1BCACNB1CACNA1CDRD4 | |
| SCHEMBL2791276 | 0.73 | TSHR (0.46) | CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL8212834 | 0.73 | CACNA2D1 (0.91) | CACNA2D1CACNA1BCACNB1CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168103-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-07-01 | — | — | US | claimed |
| EP-2061780-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2009-05-27 | — | — | EP | claimed |
| WO-2008031227-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-03-20 | — | — | WO | claimed |
| US-20100168103-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-07-01 | — | — | US | disclosed |
| US-20100168103-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-07-01 | — | — | US | disclosed |
| US-20100168103-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168103-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1B, ORAI1 | CACNA2D1 22/4885CACNA1B 2/4885CACNB1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.